| Azim Dayani, | |
|
1133 Eagles Landing Pkwy, Stockbridge, GA 30281-5085 | |
| (678) 604-1053 | |
| Not Available |
| Full Name | Azim Dayani |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology Assistant |
| Experience | 4 Years |
| Location | 1133 Eagles Landing Pkwy, Stockbridge, Georgia |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1356953921 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367H00000X | Anesthesiologist Assistant | (* (Not Available)) | Secondary |
| 367H00000X | Anesthesiologist Assistant | 10005 (Georgia) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Piedmont Henry Hospital | Stockbridge, GA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Piedmont Anesthesia Llc | 2163837972 | 155 |
News Archive
Markovian models show promise for describing postoperative pain states and, eventually, may help guide clinical decisions, a new study found.
Immune Design Corp. (IDC), a privately held biotechnology company focused on developing novel vaccines and immunotherapies for infectious disease and cancer, announced today that it has secured $32 million in Series B financing. The round was led by ProQuest Investments and was joined by current investors: The Column Group, Versant Ventures, and Alta Partners. The Series B financing brings the total amount of equity capital raised by IDC to $50 million since its inception in 2008.
CSL Behring announced today that the company has been granted Orphan Drug Designation by the United States Food and Drug Administration for its novel recombinant fusion protein linking coagulation factor IX with recombinant albumin (rIX-FP).
Across the country, states reported computer problems and long wait times as consumers tried to check out the new insurance options available through the health law's online insurance marketplaces. At the same time, though, many states reported tallies of applications and hits that exceeded expectations.
New treatment regimens for multidrug-resistant tuberculosis (MDR-TB) have shown early effectiveness in 85 percent of patients in a cohort that included many people with serious comorbidities that would have excluded them from clinical trials, according to the results of a new international study.
› Verified 5 days ago
| Entity Name | Piedmont Anesthesia Associates Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1407856594 PECOS PAC ID: 3577457183 Enrollment ID: O20040212000604 |
News Archive
Markovian models show promise for describing postoperative pain states and, eventually, may help guide clinical decisions, a new study found.
Immune Design Corp. (IDC), a privately held biotechnology company focused on developing novel vaccines and immunotherapies for infectious disease and cancer, announced today that it has secured $32 million in Series B financing. The round was led by ProQuest Investments and was joined by current investors: The Column Group, Versant Ventures, and Alta Partners. The Series B financing brings the total amount of equity capital raised by IDC to $50 million since its inception in 2008.
CSL Behring announced today that the company has been granted Orphan Drug Designation by the United States Food and Drug Administration for its novel recombinant fusion protein linking coagulation factor IX with recombinant albumin (rIX-FP).
Across the country, states reported computer problems and long wait times as consumers tried to check out the new insurance options available through the health law's online insurance marketplaces. At the same time, though, many states reported tallies of applications and hits that exceeded expectations.
New treatment regimens for multidrug-resistant tuberculosis (MDR-TB) have shown early effectiveness in 85 percent of patients in a cohort that included many people with serious comorbidities that would have excluded them from clinical trials, according to the results of a new international study.
› Verified 5 days ago
| Entity Name | North Fulton Anesthesia Associates, Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1467445262 PECOS PAC ID: 7113914466 Enrollment ID: O20040428000839 |
News Archive
Markovian models show promise for describing postoperative pain states and, eventually, may help guide clinical decisions, a new study found.
Immune Design Corp. (IDC), a privately held biotechnology company focused on developing novel vaccines and immunotherapies for infectious disease and cancer, announced today that it has secured $32 million in Series B financing. The round was led by ProQuest Investments and was joined by current investors: The Column Group, Versant Ventures, and Alta Partners. The Series B financing brings the total amount of equity capital raised by IDC to $50 million since its inception in 2008.
CSL Behring announced today that the company has been granted Orphan Drug Designation by the United States Food and Drug Administration for its novel recombinant fusion protein linking coagulation factor IX with recombinant albumin (rIX-FP).
Across the country, states reported computer problems and long wait times as consumers tried to check out the new insurance options available through the health law's online insurance marketplaces. At the same time, though, many states reported tallies of applications and hits that exceeded expectations.
New treatment regimens for multidrug-resistant tuberculosis (MDR-TB) have shown early effectiveness in 85 percent of patients in a cohort that included many people with serious comorbidities that would have excluded them from clinical trials, according to the results of a new international study.
› Verified 5 days ago
| Entity Name | Wellstar Medical Group, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1558664003 PECOS PAC ID: 6709065402 Enrollment ID: O20110127000374 |
News Archive
Markovian models show promise for describing postoperative pain states and, eventually, may help guide clinical decisions, a new study found.
Immune Design Corp. (IDC), a privately held biotechnology company focused on developing novel vaccines and immunotherapies for infectious disease and cancer, announced today that it has secured $32 million in Series B financing. The round was led by ProQuest Investments and was joined by current investors: The Column Group, Versant Ventures, and Alta Partners. The Series B financing brings the total amount of equity capital raised by IDC to $50 million since its inception in 2008.
CSL Behring announced today that the company has been granted Orphan Drug Designation by the United States Food and Drug Administration for its novel recombinant fusion protein linking coagulation factor IX with recombinant albumin (rIX-FP).
Across the country, states reported computer problems and long wait times as consumers tried to check out the new insurance options available through the health law's online insurance marketplaces. At the same time, though, many states reported tallies of applications and hits that exceeded expectations.
New treatment regimens for multidrug-resistant tuberculosis (MDR-TB) have shown early effectiveness in 85 percent of patients in a cohort that included many people with serious comorbidities that would have excluded them from clinical trials, according to the results of a new international study.
› Verified 5 days ago
| Entity Name | Mak Anesthesia Holdings, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1912452939 PECOS PAC ID: 4284917204 Enrollment ID: O20170216001563 |
News Archive
Markovian models show promise for describing postoperative pain states and, eventually, may help guide clinical decisions, a new study found.
Immune Design Corp. (IDC), a privately held biotechnology company focused on developing novel vaccines and immunotherapies for infectious disease and cancer, announced today that it has secured $32 million in Series B financing. The round was led by ProQuest Investments and was joined by current investors: The Column Group, Versant Ventures, and Alta Partners. The Series B financing brings the total amount of equity capital raised by IDC to $50 million since its inception in 2008.
CSL Behring announced today that the company has been granted Orphan Drug Designation by the United States Food and Drug Administration for its novel recombinant fusion protein linking coagulation factor IX with recombinant albumin (rIX-FP).
Across the country, states reported computer problems and long wait times as consumers tried to check out the new insurance options available through the health law's online insurance marketplaces. At the same time, though, many states reported tallies of applications and hits that exceeded expectations.
New treatment regimens for multidrug-resistant tuberculosis (MDR-TB) have shown early effectiveness in 85 percent of patients in a cohort that included many people with serious comorbidities that would have excluded them from clinical trials, according to the results of a new international study.
› Verified 5 days ago
| Entity Name | Piedmont Anesthesia Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1700474244 PECOS PAC ID: 2163837972 Enrollment ID: O20210208002823 |
News Archive
Markovian models show promise for describing postoperative pain states and, eventually, may help guide clinical decisions, a new study found.
Immune Design Corp. (IDC), a privately held biotechnology company focused on developing novel vaccines and immunotherapies for infectious disease and cancer, announced today that it has secured $32 million in Series B financing. The round was led by ProQuest Investments and was joined by current investors: The Column Group, Versant Ventures, and Alta Partners. The Series B financing brings the total amount of equity capital raised by IDC to $50 million since its inception in 2008.
CSL Behring announced today that the company has been granted Orphan Drug Designation by the United States Food and Drug Administration for its novel recombinant fusion protein linking coagulation factor IX with recombinant albumin (rIX-FP).
Across the country, states reported computer problems and long wait times as consumers tried to check out the new insurance options available through the health law's online insurance marketplaces. At the same time, though, many states reported tallies of applications and hits that exceeded expectations.
New treatment regimens for multidrug-resistant tuberculosis (MDR-TB) have shown early effectiveness in 85 percent of patients in a cohort that included many people with serious comorbidities that would have excluded them from clinical trials, according to the results of a new international study.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Azim Dayani, Po Box 117535, Atlanta, GA 30368-7535 Ph: () - | Azim Dayani, 1133 Eagles Landing Pkwy, Stockbridge, GA 30281-5085 Ph: (678) 604-1053 |
News Archive
Markovian models show promise for describing postoperative pain states and, eventually, may help guide clinical decisions, a new study found.
Immune Design Corp. (IDC), a privately held biotechnology company focused on developing novel vaccines and immunotherapies for infectious disease and cancer, announced today that it has secured $32 million in Series B financing. The round was led by ProQuest Investments and was joined by current investors: The Column Group, Versant Ventures, and Alta Partners. The Series B financing brings the total amount of equity capital raised by IDC to $50 million since its inception in 2008.
CSL Behring announced today that the company has been granted Orphan Drug Designation by the United States Food and Drug Administration for its novel recombinant fusion protein linking coagulation factor IX with recombinant albumin (rIX-FP).
Across the country, states reported computer problems and long wait times as consumers tried to check out the new insurance options available through the health law's online insurance marketplaces. At the same time, though, many states reported tallies of applications and hits that exceeded expectations.
New treatment regimens for multidrug-resistant tuberculosis (MDR-TB) have shown early effectiveness in 85 percent of patients in a cohort that included many people with serious comorbidities that would have excluded them from clinical trials, according to the results of a new international study.
› Verified 5 days ago
Sharla Phipps-mcgregor, Anesthesiologist Assistant Medicare: Accepting Medicare Assignments Practice Location: 1133 Eagles Landing Pkwy, Stockbridge, GA 30281 Phone: 678-604-1053 | |
Morgan Kristine Dawson, AA Anesthesiologist Assistant Medicare: Accepting Medicare Assignments Practice Location: 1740 Hudson Bridge Rd, Suite 1218, Stockbridge, GA 30281 Phone: 678-604-1053 | |
Cori Leanne Bruce, CAA Anesthesiologist Assistant Medicare: Accepting Medicare Assignments Practice Location: 1133 Eagles Landing Pkwy, Stockbridge, GA 30281 Phone: 678-604-2053 | |
Briana Nicole Tate-york, CAA Anesthesiologist Assistant Medicare: Accepting Medicare Assignments Practice Location: 1133 Eagles Landing Pkwy, Stockbridge, GA 30281 Phone: 678-604-1000 | |
Aleksandr Fedovskiy, PAAA Anesthesiologist Assistant Medicare: May Accept Medicare Assignments Practice Location: 1133 Eagles Landing Pkwy, Stockbridge, GA 30281 Phone: 678-604-1053 | |
Alexander Lee, Anesthesiologist Assistant Medicare: Accepting Medicare Assignments Practice Location: 1133 Eagles Landing Pkwy, Stockbridge, GA 30281 Phone: 678-604-1053 |